#daybue
LightNews LightNews
ariadiamond1998.bsky.social
THANK YOU!!! 🥹

I did her daybue earlier this month; she's my new "business/neutral" main OC 🥰

Already got a model for my other main (Pony OC), would be cool to get a model of her at somepoint; especially with all her outfits! 😍
October 20, 2026 at 9:39 PM
chemcenterbio.bsky.social
The FDA-Approved Prescription That Physically Rebuilds Autistic Brain Wiring

How Trofinetide physically rebuilds damaged synaptic architecture to reverse core autism deficits.

Source: pubmed.ncbi.nlm.nih.gov/37291210/

#autism #autismresearch #trofinetide #daybue #rettsyndrome #neuroscience
October 20, 2026 at 3:51 PM
prismmarketview.bsky.social
ACADIA Pharmaceuticals (#$ACAD) posts Q2 revenue of $308M and raises 2026 guidance to $1.24B-$1.30B on DAYBUE and NUPLAZID sales growth. Shares up ~11.9% in the month through Aug. 28.

prismmarketview.com/acadia-pharm...
ACADIA Pharmaceuticals Builds Growth Momentum as DAYBUE and NUPLAZID Sales Rise
Key Points ACADIA reported Q2 2026 revenue of approximately $308 million and net income of $31.5 million. Management increased 2026 revenue guidance to
prismmarketview.com
August 31, 2026 at 5:04 PM
chiraltech.bsky.social
New app note: Chiral analysis of Trofinetide (Daybue) for Rett syndrome.

See how CHIRALPAK ZWIX enables reliable enantiomeric separation to support research and development.

👉 Download: chiraltech.com/wp-content/u...

#ChiralChromatography #SeparationScience #CHIRALPAK
February 17, 2026 at 9:43 PM
dslevine.bsky.social
Liz Thompson, head of research and development for Acadia Pharmaceuticals, discusses Rett syndrome, how Daybue has changed the treatment landscape for people with the condition, and the company’s advancing pipeline to treat it. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/a-...
A First for Rett Syndrome with More in the Pipeline
Liz Thompson, executive vice president and head of research and development for Acadia, discusses Rett syndrome, how Daybue has changed the treatment landscape for people with the condition, and the c...
globalgenes.org
February 7, 2025 at 5:07 PM
notreload.bsky.social
$ACAD +2% [Citi gave Acadia Pharmaceuticals a Buy rating and a $33 price target, expecting growth in NUPLAZID and DAYBUE adoption soon.]
October 21, 2025 at 1:06 PM
cypresstwitch.bsky.social
Suprise April 1st Daybue. Showing off my live 2D.

www.twitch.tv/professor_cy...
Professor_Cypress - Twitch
Suprise April 1st Daybue. Showing off my live 2D.
www.twitch.tv
April 2, 2026 at 5:11 AM
skullzkidz87.bsky.social
gurl same, dumb dumb robot hasnt left my. brain since his daybue
March 7, 2025 at 6:55 PM
signalbloom.ai
ACADIA's Q2 Revenue Jumps 16% on DAYBUE Momentum, But Rising Costs Pressure Margins https://signalbloom.ai/news/ACAD/acadias-q2-revenue-jumps-16-on-daybue-momentum-but-rising-costs-pressure-margins $ACAD #Earnings via @signalbloom.ai
August 4, 2026 at 8:26 PM
asxmktsensitive.bsky.social
Neuren Pharmaceuticals ( #NEU ) has released " DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024 " on Thu 08 May at 09:02 AEST #today #UnitedStates #ClinicalTrials #Australia #ASX
Neuren Pharmaceuticals share price
Neuren Pharmaceuticals (ASX:NEU) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Neuren Pharmaceuticals’s share pric
grafa.com
May 7, 2025 at 11:07 PM
asxmktsensitive.bsky.social
Neuren Pharmaceuticals ( #NEU ) has released " Neuren receives DAYBUE sales milestone payment of US$50m " on Fri 28 Feb at 11:45 AEST #today #UnitedStates #ClinicalTrials #Australia #ASX
Neuren Pharmaceuticals share price
Neuren Pharmaceuticals (ASX:NEU) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Neuren Pharmaceuticals’s share pric
grafa.com
February 28, 2025 at 12:52 AM
asxmktsensitive.bsky.social
Neuren Pharmaceuticals ( #NEU ) has released " DAYBUE (trofinetide) 2024 net sales US$348 million " on Thu 27 Feb at 10:01 AEST #today #UnitedStates #ClinicalTrials #Australia #ASX
Neuren Pharmaceuticals share price
Neuren Pharmaceuticals (ASX:NEU) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Neuren Pharmaceuticals’s share pric
grafa.com
February 26, 2025 at 11:07 PM
surajworld.bsky.social
Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data

Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data
Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data
Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data
suraj.world
May 8, 2025 at 12:19 AM
longtail-news.bsky.social
Feed: "Stockhead"
By: Tim Boreham on Monday, May 18, 2026
Dr Boreham’s Crucible: Neuren looks beyond Rett as Daybue royalties surge
Daybue turned Neuren into a biotech heavyweight. Now investors want to know whether the company’s next wave of rare disease drugs can repeat the trick.
stockhead.com.au
May 19, 2026 at 10:19 AM
longtail-news.bsky.social
Feed: "Endpoints News"
By: Anna Brown on Thursday, September 18, 2025
Acadia delays UK drug launch plans due to high market entry barrier for biotechs
Acadia Pharmaceuticals' plans to seek UK approval for its Rett syndrome drug Daybue are 'postponed indefinitely' due to high taxes and reimbursement challenges in the country, CEO Catherine Adams told Endpoints News in an interview.
endpoints.news
September 19, 2025 at 1:35 AM
longtail-news.bsky.social
Feed: "Stockhead"
By: Tim Boreham on Thursday, August 7, 2025
Health Check: Neuren says the US Rett syndrome market is a case of glass half full
Neuren Pharmaceutical's reports boosted sales of the Rett syndrome drug Daybue, but two-thirds of US patients are yet to try it.
stockhead.com.au
August 7, 2025 at 4:20 PM
longtail-news.bsky.social
Feed: "Stockhead"
By: Tim Boreham on Thursday, May 8, 2025
Health Check: Neuren says more patients are staying the course as US Daybue sales lift
Neuren Pharmaceuticals says fewer US Rett syndrome patients are discontinuing its breakthrough drug Daybue.
stockhead.com.au
May 8, 2025 at 5:34 AM
blueresearch.bsky.social
Acadia Pharmaceuticals announces Daybue Stix available in U.S.
Reported Tuesday, Apr 7 - 9:19am EDT (TheFly subscription required to read more.)
thefly.com
April 7, 2026 at 1:21 PM
blueresearch.bsky.social
Acadia Pharmaceuticals announces FDA approval of Daybue Stix for oral solution
Reported Friday, Dec 12 - 8:01am EST (TheFly subscription required to read more.)
thefly.com
December 12, 2025 at 1:11 PM
sugarpopspete.bsky.social
c.org/vK6WtQsQL5
Sign the Petition
Ensure timely, managed access to Daybue for Canadians with Rett Syndrome
c.org
February 11, 2026 at 2:34 PM
mithatabakan.bsky.social
Mizuho, Daybue lansmanı nedeniyle Acadia Pharma hisse senedi fiyat hedefini 39 dolara düşürdü
Mizuho, Daybue lansmanı nedeniyle Acadia Pharma hisse senedi fiyat hedefini 39 dolara düşürdü
dlvr.it
February 28, 2024 at 12:24 PM
tylordianwake.bsky.social
My 2025 film tier list
January daybue
Looks like we already found the best animated film of the year!
January 28, 2025 at 10:41 PM
stocktitan.net
#ACAD Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-reports-second-quarter-2026-financial-tu5xo3ifz820.html
Acadia expects Phase 2 Alzheimer’s psychosis results in Sept.–Oct.
GAAP DAYBUE sales rose 30% to $125M; GAAP NUPLAZID sales were $183M; 2026 revenue guidance is $1.24B-$1.30B, with Phase 2 results expected Sept.-Oct.
www.stocktitan.net
August 4, 2026 at 8:05 PM
stocktitan.net
#ACAD Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2026-financial-results-my92urou4zqw.html
Acadia posts $268M quarter as Alzheimer’s study nears fall data
DAYBUE sales reached $101M and NUPLAZID added $167M, bringing Q1 revenue to $268M. Acadia kept 2026 targets and still expects Phase 2 data by Oct.
www.stocktitan.net
May 6, 2026 at 8:06 PM
stocktitan.net
#ACAD Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-announces-daybue-stix-trofinetide-is-now-pk6yynr2203j.html
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Inc. today announced DAYBUE ® STIX for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration in...
www.stocktitan.net
April 7, 2026 at 1:05 PM